查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1654649

全球鼻腔给药技术市场 - 2025 至 2033 年

Global Nasal Drug Delivery Technology Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 179 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球鼻腔给药技术市场规模达到 816.9 亿美元，预计到 2033 年将达到 1,369.7 亿美元，2025-2033 年预测期内的复合年增长率为 6.7%。

鼻腔给药技术是指透过鼻腔给药来达到治疗效果的技术。这种药物输送途径因其方便、有效，且能够绕过胃肠系统和肝臟首过代谢，从而减少副作用并提高药物的生物利用度，而得到越来越多的应用。鼻腔给药技术是利用鼻腔喷雾剂、粉剂和气雾剂将药物透过鼻黏膜直接输送到血液中。这种方法特别有利于递送胜肽、蛋白质、疫苗和其他药物，这些药物在胃肠道中降解或吸收不良而口服时可能无效。

由于鼻腔给药技术具有非侵入性、便利性和患者依从性提高的特点，市场对鼻腔给药技术的需求正在迅速增长。这些技术的采用率受到多种因素的推动，其中包括在慢性病管理中的应用日益增多，例如，根据美国疾病管制与预防中心的数据，估计美国有 1.29 亿人患有至少 1 种主要慢性病。根据世界卫生组织的数据，到2030年，全球每6人中就有1人年龄在60岁或以上，这一老龄化人口需要更简单、更可接受的治疗方案，这增加了对鼻腔给药技术的需求。

市场动态：

驱动因素与约束因素

奈米技术不断进步

奈米技术的不断进步极大地推动了鼻腔药物输送技术市场的成长，并有望在预测期内透过开发更高效、更有针对性的药物输送系统来推动市场发展。这些创新提高了经鼻给药的药物的稳定性、生物利用度和患者依从性，增强了药物的有效性。

例如，2024 年 10 月，来自莫哈里奈米科学技术研究所 (INST) 的研究人员开发了一种新型药物传输系统，用于治疗中枢神经系统结核病 (CNS-TB)。这种尖端方法透过鼻腔途径将抗结核病 (TB) 药物直接输送到大脑，克服了血脑屏障 (BBB) 带来的限制。

奈米技术涉及使用奈米粒子，可以将药物直接穿过鼻粘膜进入血液。这些奈米粒子可以保护药物免于降解，并增强其稳定性和生物利用度。这对于胜肽和蛋白质特别有益，因为它们口服时通常不稳定。

此外，2024 年 11 月，Virpax Pharmaceuticals, Inc. 与美国国家推动转化科学中心 (NCATS) 的合作研发协议获得延期。此次合作是为了继续开发 Virpax 的候选产品 NES100（一种鼻内肽），用于治疗急性和慢性非癌症疼痛。 NES100 是一种基于奈米技术输送方法的脑啡肽药物产品。脑啡肽是一种天然存在的（内源性）胜肽，不易以其原始形式给药。

不良反应和安全问题

不良反应和安全问题是阻碍鼻腔给药技术市场成长的重大挑战。这些问题可能会影响患者和医疗保健提供者对鼻腔给药系统的接受度和采用。鼻腔给药有时会引起鼻黏膜的刺激或过敏反应。这会导致不适，且患者不愿意使用鼻腔喷剂或粉末。干燥、打喷嚏或鼻塞等局部副作用是鼻腔给药技术的常见问题。

例如，使用含有皮质类固醇的鼻腔喷剂来治疗过敏，会引起局部刺激，导致流鼻血或鼻腔灼热感。这些不良影响可能会使患者不愿意继续治疗。

虽然鼻腔给药最大限度地减少了首过代谢，但仍存在全身性吸收的风险，特别是对于旨在局部作用的药物。这可能会导致意想不到的全身性副作用，从而限制某些药物在鼻腔製剂中的使用。例如，对于像鼻减充血剂这样用于局部作用的药物，仍可能会发生全身吸收，可能导致心率加快和血压增加等心血管影响。

目录

第一章：市场介绍和范围

  • 报告目标
  • 报告范围和定义
  • 报告范围

第 2 章：高阶主管见解与关键要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 以剂型分类的片段
  • 按应用程式截取的程式码片段
  • 按配销通路分类的片段
  • 按地区分类的片段

第 3 章：动态

  • 影响因素
    • 驱动程式
      • 奈米技术不断进步
      • 技术合作与合併不断增多
    • 限制
      • 不良反应和安全问题
    • 机会
    • 影响分析

第四章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的成熟领导者
    • 拥有成熟产品的市场领导者
  • 新兴创业公司和关键创新者
  • CXO 观点
  • 最新进展与突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT 分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态

第 5 章：鼻腔给药技术市场（依剂型划分）

  • 喷雾剂
  • 掉落
  • 粉末
  • 啫咖哩

第 6 章：鼻腔给药技术市场（依应用）

  • 呼吸系统疾病
    • 气喘
    • 慢性阻塞性肺病 (COPD)
    • 过敏性鼻炎
    • 鼻窦炎
    • 其他的
  • 中枢神经系统疾病
    • 偏头痛
    • 帕金森氏症
    • 阿兹海默症
  • 疼痛管理
  • 其他的

第 7 章：鼻腔给药技术市场（依配销通路）

  • 医院药房
  • 网路药局
  • 零售药局

第 8 章：鼻腔给药技术市场，按区域市场分析和成长机会

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第九章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的关键发展
  • 公司基准化分析

第十章：公司简介

  • Pfizer Inc.
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 关键进展
    • SWOT 分析
  • Becton, Dickinson and Company
  • AstraZeneca PLC
  • AptarGroup, Inc.
  • MetP Pharma AG
  • GlaxoSmithKline Inc.
  • Hikma Pharmaceuticals PLC
  • Currax Pharmaceuticals LLC.
  • Tonix Medicines, Inc.
  • Johnson & Johnson

第 11 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 12 章：附录

简介目录
Product Code: MD9094

The global nasal drug delivery technology market reached US$ 81.69 billion in 2024 and is expected to reach US$ 136.97 billion by 2033, growing at a CAGR of 6.7% during the forecast period 2025-2033.

Nasal drug delivery technology refers to the administration of drugs through the nasal cavity to achieve therapeutic effects. This route of drug delivery is increasingly being used for its convenience, efficiency, and ability to bypass the gastrointestinal system and hepatic first-pass metabolism, which can reduce side effects and improve drug bioavailability. Nasal drug delivery technology involves the use of nasal sprays, powders and aerosols to deliver drugs directly into the bloodstream via the nasal mucosa. This method is particularly beneficial for the delivery of peptides, proteins, vaccines and other drugs that may not be effective when administered orally due to degradation in the gastrointestinal tract or poor absorption.

The market demand for nasal drug delivery technology is growing rapidly due to its non-invasive nature, convenience and improved patient compliance. The adoption rate of these technologies is being driven by several factors including increasing applications in chronic disease management, for instance, according to the Centers for Disease Control and Prevention, an estimated 129 million people in the US have at least 1 major chronic disease. According to the World Health Organization, by 2030, 1 in 6 people in the world will be aged 60 years or over, this aging population requires easier and more acceptable treatment options, which increases the demand for nasal drug delivery technology.

Market Dynamics: Drivers & Restraints

Rising advancements in nanotechnology

The rising advancements in nanotechnology are significantly driving the growth of the nasal drug delivery technology market and are expected to drive the market over the forecast period by enabling the development of more efficient and targeted drug delivery systems. These innovations enhance the effectiveness of drugs delivered through the nasal route by improving their stability, bioavailability and patient compliance.

For instance, in October 2024, researchers from the Institute of Nano Science and Technology (INST), Mohali, developed a novel drug delivery system to treat Central Nervous System Tuberculosis (CNS-TB). This cutting-edge method delivers anti-tuberculosis (TB) drugs directly to the brain through the nasal route, overcoming the limitations posed by the blood-brain barrier (BBB).

Nanotechnology involves the use of nanoparticles that can carry drugs directly across the nasal mucosa into the bloodstream. These nanoparticles can protect drugs from degradation, enhancing their stability and bioavailability. This is particularly beneficial for peptides and proteins, which are typically unstable when administered orally.

Additionally, in November 2024, Virpax Pharmaceuticals, Inc. was granted an extension of its cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS). This collaboration is for the continued development of Virpax's product candidate, NES100, an intranasal peptide, for the management of acute and chronic non-cancer pain. NES100 is an enkephalin drug product based on a type of nanotechnology delivery approach. Enkephalin is a naturally occurring (endogenous) peptide that is not easily administered in its original form.

Adverse effects and safety concerns

Adverse effects and safety concerns are significant challenges hampering the growth of the nasal drug delivery technology market. These issues can impact the acceptability and adoption of nasal drug delivery systems by both patients and healthcare providers. Nasal drug delivery can sometimes cause irritation or allergic reactions in the nasal mucosa. This can lead to discomfort and patient reluctance to use nasal sprays or powders. Localized side effects such as dryness, sneezing or nasal congestion are common issues with nasal drug delivery technologies.

For instance, the use of corticosteroids in nasal sprays for managing allergies can result in local irritation, leading to nosebleeds or a burning sensation in the nasal passages. Such adverse effects can discourage patients from continuing treatment.

Although nasal delivery minimizes first-pass metabolism, there is still a risk of systemic absorption, especially for drugs that are intended to act locally. This can lead to unintended systemic side effects, which can limit the use of certain drugs in nasal formulations. For instance, for drugs intended for local action like nasal decongestants, systemic absorption may still occur, potentially leading to cardiovascular effects such as increased heart rate and blood pressure.

Segment Analysis

The global nasal drug delivery technology market is segmented based on dosage form, application, distribution channel and region.

Application:

The respiratory diseases segment is expected to dominate the nasal drug delivery technology market share

Nasal drug delivery systems are highly effective for treating allergic rhinitis and asthma, which are common respiratory conditions. These conditions require frequent medication administration, and nasal sprays are particularly suitable due to their quick onset of action and localized effects. Nasal corticosteroids are the primary drugs used in this segment, offering targeted anti-inflammatory action directly to the nasal mucosa, which minimizes systemic side effects.

For instance, in January 2023, Airsupra (albuterol/budesonide), formerly known as PT027, which is developed by AstraZeneca and Avillion, was approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older. Airsupra is a fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhaled corticosteroid (ICS) in the US.

The nasal route allows for quick absorption of drugs into the bloodstream, which is particularly advantageous for managing acute symptoms of respiratory diseases like asthma attacks. Drugs administered via the nasal route can bypass the gastrointestinal system and avoid the first-pass metabolism in the liver, ensuring higher bioavailability and faster therapeutic effects.

Geographical Analysis

North America is expected to hold a significant position in the nasal drug delivery technology market share

Major pharmaceutical companies and research institutions in North America especially in the United States, are investing heavily in the development and commercialization of nasal drug delivery systems. Companies like Pfizer, Johnson & Johnson, Amneal Pharmaceuticals, Inc. and other emerging players have been at the forefront, with nasal drug formulations being a key component of their respiratory disease management strategies by FDA approvals.

For instance, in April 2024, Amneal Pharmaceuticals, Inc. announced the availability of Over the Counter (OTC) Naloxone Hydrochloride (Naloxone HCI) Nasal Spray, USP, 4mg, following Abbreviated New Drug Application approval from the U.S. Food and Drug Administration (FDA). Amneal's Naloxone HCI Nasal Spray, manufactured in the U.S., is a generic equivalent to OTC NARCAN HCI Nasal Spray, a medication that is widely used to help treat drug overdose from opioids, including heroin, fentanyl and prescription opioid medications.

Additionally, in September 2024, Renaissance Lakewood, LLC manufactured neffy. The FDA approved and became the first and only needle-free, intranasal spray treatment for Type I allergic reactions, including anaphylaxis in adults and children. neffy is an easy-to-carry and easy-to-use epinephrine medication alternative to needle-based treatments for potentially life-threatening allergic reactions. neffy marks the first regulatory approval worldwide for epinephrine delivered as an intra-nasal spray.

Asia-Pacific is growing at the fastest pace in the nasal drug delivery technology market

The healthcare infrastructure in the Asia-Pacific region has been rapidly improving. Countries like India, China, Japan and South Korea are investing heavily in healthcare, including the establishment of new medical facilities and research centers. For instance, according to the India Brand Equity Foundation (IBEF), under the PLI scheme for Medical Devices, till now, a total of 26 projects have been approved, with a committed investment of US$ 147 million. These rising investments and developments have facilitated the adoption of advanced drug delivery technologies, including nasal drug delivery systems.

In March 2024, Aurobindo Pharma added 1.28% to Rs 1,002.05 after the drug maker received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Mometasone Furoate Monohydrate Nasal Spray. The approved drug is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Nasonex Nasal Spray of Organon LLC. The product will be launched in Q1 FY25. Mometasone Furoate Monohydrate Nasal Spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis, in adults and pediatric patients 2 years of age and older.

The APAC region is witnessing rapid adoption of new drug delivery technologies, including nanotechnology and controlled release systems for nasal drug delivery. Companies in the region along with strategic partnerships and mergers, innovating and distributing nasal formulations that cater to regional needs. For instance, Altamira Therapeutics Ltd. announced that its associate company Altamira Medica Ltd. agreed with its partner Nuance Pharma, Shanghai, China to extend the territory covered by their exclusive license and distribution agreement for Bentrio nasal spray by several countries across South East and East Asia.

Competitive Landscape

The major global players in the nasal drug delivery technology market include Pfizer Inc., Becton, Dickinson and Company, AstraZeneca PLC, AptarGroup, Inc., MetP Pharma AG, GlaxoSmithKline Inc., Hikma Pharmaceuticals PLC, Currax Pharmaceuticals LLC., Tonix Medicines, Inc., Johnson & Johnson and among others.

Key Developments

  • In October 2024, Aero Pump and Resyca announced their collaboration in the launch of the innovative Ultra Soft Nasal Pump Spray. Available for licensing immediately, this co-developed system represents a new frontier in nasal drug delivery, offering enhanced delivery efficiency, precision and comfort for users.
  • In April 2024, Aptar Pharma launched APF Futurity, its first metal-free, multidose nasal spray pump developed to deliver nasal saline and other comparable over-the-counter (OTC) formulations. APF Futurity is made from polyolefin materials with no metal parts or recycling disruptors, thereby minimizing separation efforts in recycling streams and supporting a higher quality of recyclates.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global nasal drug delivery technology market report delivers a detailed analysis with 62 key tables, more than 54 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Dosage Form
  • 2.4. Snippet by Application
  • 2.5. Snippet by Distribution Channel
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Advancements in Nanotechnology
      • 3.1.1.2. Rising Technological Collaborations and Mergers
    • 3.1.2. Restraints
      • 3.1.2.1. Adverse Effects and Safety Concerns
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Nasal Drug Delivery Technology Market, By Dosage Form

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
    • 5.1.2. Market Attractiveness Index, By Dosage Form
  • 5.2. Sprays*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Drops
  • 5.4. Powders
  • 5.5. Gels

6. Nasal Drug Delivery Technology Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Respiratory Diseases*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Asthma
    • 6.2.4. Chronic Obstructive Pulmonary Disease (COPD)
    • 6.2.5. Allergic Rhinitis
    • 6.2.6. Sinusitis
    • 6.2.7. Others
  • 6.3. CNS Disorders
    • 6.3.1. Migraine
    • 6.3.2. Parkinson's Disease
    • 6.3.3. Alzheimer's Disease
  • 6.4. Pain Management
  • 6.5. Others

7. Nasal Drug Delivery Technology Market, By Distribution Channel

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 7.1.2. Market Attractiveness Index, By Distribution Channel
  • 7.2. Hospital Pharmacies*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Online Pharmacies
  • 7.4. Retail Pharmacies

8. Nasal Drug Delivery Technology Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Form
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Pfizer Inc.*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Financial Overview
    • 10.1.4. Key Developments
    • 10.1.5. SWOT Analysis
  • 10.2. Becton, Dickinson and Company
  • 10.3. AstraZeneca PLC
  • 10.4. AptarGroup, Inc.
  • 10.5. MetP Pharma AG
  • 10.6. GlaxoSmithKline Inc.
  • 10.7. Hikma Pharmaceuticals PLC
  • 10.8. Currax Pharmaceuticals LLC.
  • 10.9. Tonix Medicines, Inc.
  • 10.10. Johnson & Johnson

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us